131 related articles for article (PubMed ID: 23447136)
1. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.
Manousakis G; Koch J; Sommerville RB; El-Dokla A; Harms MB; Al-Lozi MT; Schmidt RE; Pestronk A
Muscle Nerve; 2013 Sep; 48(3):440-4. PubMed ID: 23447136
[TBL] [Abstract][Full Text] [Related]
2. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab.
Cafuir L; Lawson D; Desai N; Kesner V; Voloschin A
J Immunother Cancer; 2018 Jan; 6(1):11. PubMed ID: 29382383
[TBL] [Abstract][Full Text] [Related]
4. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
Sepúlveda M; Martinez-Hernandez E; Gaba L; Victoria I; Sola-Valls N; Falgàs N; Casanova-Molla J; Graus F
Muscle Nerve; 2017 Dec; 56(6):E162-E167. PubMed ID: 28439919
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
6. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.
Bernardo SG; Moskalenko M; Pan M; Shah S; Sidhu HK; Sicular S; Harcharik S; Chang R; Friedlander P; Saenger YM
Melanoma Res; 2013 Feb; 23(1):47-54. PubMed ID: 23262440
[TBL] [Abstract][Full Text] [Related]
7. Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
Thaipisuttikul I; Chapman P; Avila EK
J Immunother; 2015; 38(2):77-9. PubMed ID: 25658617
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
9. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma.
Modjtahedi BS; Maibach H; Park S
Cutan Ocul Toxicol; 2013 Oct; 32(4):341-3. PubMed ID: 23713627
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
Libon F; Arrese JE; Rorive A; Nikkels AF
Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
Bhatia S; Huber BR; Upton MP; Thompson JA
J Immunother; 2009; 32(2):203-5. PubMed ID: 19238020
[TBL] [Abstract][Full Text] [Related]
13. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab for advanced melanoma: a nursing perspective.
Ledezma B
Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.
Jones PS; Cahill DP; Brastianos PK; Flaherty KT; Curry WT
Neurosurg Focus; 2015 Mar; 38(3):E5. PubMed ID: 25727227
[TBL] [Abstract][Full Text] [Related]
18. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
19. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Hanaizi Z; van Zwieten-Boot B; Calvo G; Lopez AS; van Dartel M; Camarero J; Abadie E; Pignatti F
Eur J Cancer; 2012 Jan; 48(2):237-42. PubMed ID: 22030452
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab-associated bilateral optic neuropathy.
Yeh OL; Francis CE
J Neuroophthalmol; 2015 Jun; 35(2):144-7. PubMed ID: 25647225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
